Bio-Rad receives pre-market approval for HIV test
Bio-Rad Laboratories (NYSE:BIO) announced Monday it received FDA premarket approval for its fourth generation
Breaking News
Bio-Rad Laboratories (NYSE:BIO) announced Monday it received FDA premarket approval for its fourth generation